Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) closed the day trading at $7.41 down -2.24% from the previous closing price of $7.58. In other words, the price has decreased by -$2.24 from its previous closing price. On the day, 1.79 million shares were traded. XERS stock price reached its highest trading level at $7.6 during the session, while it also had its lowest trading level at $7.365.
Ratios:
For a better understanding of XERS, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 13.42 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 123.32. For the most recent quarter (mrq), Quick Ratio is recorded 1.35 and its Current Ratio is at 1.93.
Upgrades & Downgrades
In the most recent recommendation for this company, Barclays on December 09, 2025, initiated with a Overweight rating and assigned the stock a target price of $9.
Piper Sandler Downgraded its Overweight to Neutral on November 11, 2024, while the target price for the stock was maintained at $3.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 08 ’26 when McCulloch Kevin sold 15,000 shares for $8.00 per share. The transaction valued at 120,000 led to the insider holds 1,685,426 shares of the business.
KEVIN MCCULLOCH bought 60,000 shares of XERS for $432,600 on Jan 08 ’26. On Jan 05 ’26, another insider, Shannon John Patrick Jr, who serves as the insider of the company, sold 24,907 shares for $7.08 each. As a result, the insider received 176,257 and left with 2,705,346 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XERS now has a Market Capitalization of 1229499008 and an Enterprise Value of 1395554944. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.62. Its current Enterprise Value per Revenue stands at 5.244 whereas that against EBITDA is 49.777.
Stock Price History:
The Beta on a monthly basis for XERS is 0.64, which has changed by 1.3687501 over the last 52 weeks, in comparison to a change of 0.15507638 over the same period for the S&P500. Over the past 52 weeks, XERS has reached a high of $10.08, while it has fallen to a 52-week low of $3.14. The 50-Day Moving Average of the stock is 1.06%, while the 200-Day Moving Average is calculated to be 15.05%.
Shares Statistics:
Over the past 3-months, XERS traded about 2.56M shares per day on average, while over the past 10 days, XERS traded about 3170920 shares per day. A total of 165.53M shares are outstanding, with a floating share count of 155.16M. Insiders hold about 6.49% of the company’s shares, while institutions hold 59.10% stake in the company. Shares short for XERS as of 1767139200 were 16522754 with a Short Ratio of 6.45, compared to 1764288000 on 15974039. Therefore, it implies a Short% of Shares Outstanding of 16522754 and a Short% of Float of 10.35.
Earnings Estimates
The market rating of Xeris Biopharma Holdings Inc (XERS) is currently shaped by the ongoing analysis conducted by 2.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $0.01, with high estimates of $0.01 and low estimates of $0.01.
Analysts are recommending an EPS of between $0.17 and -$0.04 for the fiscal current year, implying an average EPS of $0.06. EPS for the following year is $0.31, with 2.0 analysts recommending between $0.41 and $0.22.
Revenue Estimates
1 analysts predict $86M in revenue. The current quarter. It ranges from a high estimate of $86M to a low estimate of $86M. As of. The current estimate, Xeris Biopharma Holdings Inc’s year-ago sales were $60.1MFor the next quarter, 1 analysts are estimating revenue of $83.7M. There is a high estimate of $86.9M for the next quarter, whereas the lowest estimate is $81.5M.
A total of 1 analysts have provided revenue estimates for XERS’s current fiscal year. The highest revenue estimate was $292M, while the lowest revenue estimate was $292M, resulting in an average revenue estimate of $292M. In the same quarter a year ago, actual revenue was $203.07MBased on 6 analysts’ estimates, the company’s revenue will be $368M in the next fiscal year. The high estimate is $432.3M and the low estimate is $337.9M.
